Cancer Family
Liver Epithelial Neoplasm
CI-CAN-00000217Explore in graph →
Non-malignant784 active trials14 approved drugs17 evidence items
- NCIt
- C7106
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000217Explore in graph →
Clinical trials
3,372 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04066543 | TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 40 | Zhejiang Cancer HospitalOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT02733809 | Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 4 | 40 | King Saud UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT03905967 |
| TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC(TACE) |
| unknown |
| Phase 3 |
| 336 |
| Sun Yat-sen UniversityOTHER |
| 1 |
| Aug 20, 2019 |
| clinicaltrials |
| NCT04053972 | The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial. | unknown | Phase 3 | 377 | Sun Yat-sen UniversityOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT04053985 | The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 3 | 206 | Sun Yat-sen UniversityOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT04052152 | Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 9, 2019 | clinicaltrials |
| NCT03965546 | ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer | unknown | Early Phase 1 | 27 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 8, 2019 | clinicaltrials |
| NCT04048317 | Effectiveness of Drug Eluting TACE in Primary HCC | unknown | Early Phase 1 | 75 | Assiut UniversityOTHER | 0 | Aug 7, 2019 | clinicaltrials |
| NCT01936233 | Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery | unknown | Phase 3 | 112 | Fudan UniversityOTHER | 1 | Aug 5, 2019 | clinicaltrials |
| NCT02529761 | TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma | unknown | N/A | 330 | Air Force Military Medical University, ChinaOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT04035876 | Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant | unknown | Phase 1 / Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT04032392 | Immunotherapy of Advanced Hepatitis B Related Hepatocellular Carcinoma With γδT Cells | unknown | Phase 1 | 20 | Beijing 302 HospitalOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT04021056 | Observational Study on Patients With Hepatocellular Carcinoma (HCC) | unknown | — | 3,000 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT04014101 | SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma(SHR-1210) | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT04012021 | EXplanted LIver and Ex-vivo Pancreatic Specimen Evaluation by 7 TESLA MRI(EXLIPSE) | unknown | N/A | 30 | University of PisaOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT01570166 | Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma | unknown | N/A | 210 | Sun Yat-sen UniversityOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT03996681 | TACE Combined With Methylcantharidimide Tablets in the Treatment of Large and Unresectable Hepatocellular Carcinoma | unknown | Phase 4 | 22 | Suzhou Municipal HospitalOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT03981848 | Radiomics-based Non-invasive Classifier Research for HCC-related Liver Transplantation | unknown | — | 200 | Zhejiang UniversityOTHER | 0 | Jun 11, 2019 | clinicaltrials |
| NCT03966209 | Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant | unknown | Phase 1 | 20 | Shanghai Zhongshan HospitalOTHER | 1 | May 31, 2019 | clinicaltrials |
| NCT03950102 | SBRT as Bridging Therapy for Hepatocellular Carcinoma Patients on Transplant Waitlist | unknown | N/A | 40 | The University of Hong KongOTHER | 1 | May 28, 2019 | clinicaltrials |
| NCT03880721 | By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation | unknown | — | 200 | Chinese PLA General HospitalOTHER | 1 | May 24, 2019 | clinicaltrials |
| NCT03138044 | Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment of the Large Hepatocellular Carcinoma | unknown | N/A | 12 | The National Ribat UniversityOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT03939845 | A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for Hepatocellular Carcinoma With Portal Vein Tumor Thrombi | unknown | Phase 3 | 180 | Shanghai Zhongshan HospitalOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT03812770 | Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC | unknown | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03914352 | A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection | unknown | N/A | 40 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03899415 | TCR-Redirected T Cells Therapy in Patient With HBV Related HCC | unknown | Phase 1 | 10 | Beijing 302 HospitalOTHER | 1 | Apr 10, 2019 | clinicaltrials |
| NCT03908840 | Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma | unknown | Phase 1 | 12 | Evolve BiologicsINDUSTRY | 1 | Apr 9, 2019 | clinicaltrials |
| NCT03869151 | Pretreatment Lymphocyte Monocyte Ratio on Outcome HCC Patients | unknown | — | 1 | Amany Aboalenen AminOTHER | 0 | Apr 2, 2019 | clinicaltrials |
| NCT03857815 | Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT03881501 | Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma | unknown | — | 2 | Huazhong University of Science and TechnologyOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01891539 | Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma(DEBDOX) | unknown | — | 100 | International Group of Endovascular OncologyOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03853928 | Probiotics in the Prevention of Hepatocellular Carcinoma in Cirrhosis | unknown | N/A | 280 | Austral University, ArgentinaOTHER | 0 | Feb 27, 2019 | clinicaltrials |
| NCT02232490 | Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L(Hepko-V5) | unknown | Phase 3 | 120 | Immunitor LLCINDUSTRY | 1 | Feb 26, 2019 | clinicaltrials |
| NCT03851887 | The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT03851939 | The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 65 | Sun Yat-sen UniversityOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT03734068 | Chemoembolization Using LifePearl Polyethylene Glycol Drug Eluting Microspheres With Doxorubicin in HCC(LIFDOX) | unknown | — | 100 | International Group of Endovascular OncologyOTHER | 1 | Feb 21, 2019 | clinicaltrials |
| NCT03839550 | Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection | unknown | Phase 2 | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03313596 | Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC | unknown | Phase 3 | 180 | Huazhong University of Science and TechnologyOTHER | 1 | Feb 4, 2019 | clinicaltrials |
| NCT03614546 | Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma | unknown | N/A | 200 | The Third Xiangya Hospital of Central South UniversityOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT03812783 | HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT03807947 | Radial Versus Femoral Access for Superselective Embolization of Hepatocellular Carcinoma | unknown | N/A | 74 | Humanitas Clinical and Research CenterOTHER | 1 | Jan 17, 2019 | clinicaltrials |
| NCT03793322 | The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular Carcinoma | unknown | Phase 1 | 100 | Zhujiang HospitalOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT03793725 | A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC(HZ-T-PD1-APA) | unknown | Phase 2 | 30 | Yanqiao ZhangOTHER | 0 | Jan 4, 2019 | clinicaltrials |
| NCT03116945 | Novel Gallium Imaging in Hepatocellular Carcinoma | unknown | Phase 2 | 18 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03775395 | HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC | unknown | Phase 3 | 250 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03730675 | Irradiation Stent Placement Plus TACE for HCC and PVTT | unknown | N/A | 308 | Zhongda HospitalOTHER | 1 | Dec 21, 2018 | clinicaltrials |
| NCT02759601 | Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)(CHR-2845) | unknown | Phase 1 / Phase 2 | 69 | Queen Mary University of LondonOTHER | 1 | Dec 20, 2018 | clinicaltrials |
| NCT03722875 | SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery | unknown | N/A | 45 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03777475 | the Effect of Different Oxaliplatin Dose in Transarterial Infusion (TAI) in Unresectable Hepatocellular Carcinoma | unknown | N/A | 350 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2018 | clinicaltrials |
| NCT03517332 | Circulating Tumor DNA Exposure in Peripheral Blood | unknown | — | 10,000 | Quantgene Inc.INDUSTRY | 2 | Nov 20, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Aug 26, 2019source: clinicaltrials